NASDAQ:CPRX

Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

$16.46

-0.52 (-3.06%)

(As of 12/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $16.19
▼
$17.09
50-Day Range: $12.25
▼
$17.51
52-Week Range: $5.24
▼
$18.39

Volume: 2.30 million shs
Average Volume: 1.97 million shs
Market Capitalization: $1.71 billion

P/E Ratio: 26.98
Dividend Yield: N/A
Price Target: $17.13

Catalyst Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 4.0% Upside
$17.13 Price Target
Short Interest: Healthy
6.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.01
Upright™ Environmental Score
News Sentiment: 0.88
Based on 3 Articles This Week
Insider Trading: Selling Shares
$21.11 M Sold Last Quarter
Proj. Earnings Growth: 19.18%
From $0.73 to $0.87 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

137th out of 1,023 stocks

Pharmaceutical Preparations Industry

52nd out of 501 stocks

1.4

Analyst's Opinion

Consensus Rating
Catalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.13, Catalyst Pharmaceuticals has a forecasted upside of 4.0% from its current price of $16.46.
Amount of Analyst Coverage
Catalyst Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
6.84% of the float of Catalyst Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Catalyst Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Catalyst Pharmaceuticals has recently decreased by 17.25%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Catalyst Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Catalyst Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalyst Pharmaceuticals has received a 51.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Catalyst Pharmaceuticals is -2.01.

3.8

News and Social Media Coverage

News Sentiment
Catalyst Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Catalyst Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
44 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 144% compared to the previous 30 days.
MarketBeat Follows
23 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 188% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,108,453.00 in company stock.
Percentage Held by Insiders
14.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.16% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Catalyst Pharmaceuticals are expected to grow by 19.18% in the coming year, from $0.73 to $0.87 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalyst Pharmaceuticals is 26.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalyst Pharmaceuticals is 26.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.26.
Price to Book Value per Share Ratio
Catalyst Pharmaceuticals has a P/B Ratio of 8.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Stock News Headlines

November 10, 2022 | marketbeat.com

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report? (CPRX)

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

December 2, 2022 | finance.yahoo.com

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

December 1, 2022 | americanbankingnews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) Head to Head Analysis

November 29, 2022 | americanbankingnews.com

Catalyst Pharmaceuticals (NASDAQ:CPRX) versus Biophytis (NASDAQ:BPTS) Head-To-Head Comparison

November 24, 2022 | benzinga.com

Catalyst Pharmaceuticals Insider Trades Send a Signal

November 24, 2022 | benzinga.com

Catalyst Pharmaceuticals Director Trades $1.59M In Company Stock

November 23, 2022 | benzinga.com

Catalyst Pharmaceuticals President and CEO Sold $7.77M In Company Stock

November 23, 2022 | markets.businessinsider.com

Follow Analyst Andrew Fein for a 100% Success Rate on Catalyst Pharma (NASDAQ:CPRX)

November 18, 2022 | benzinga.com

VP At This Health Care Company Sells $946K of Stock

November 18, 2022 | benzinga.com

Massive Insider Trade At Catalyst Pharmaceuticals

November 16, 2022 | benzinga.com

Catalyst Pharmaceuticals Chief Strategy Officer Trades Company's Stock

November 15, 2022 | seekingalpha.com

Catalyst Pharmaceuticals: Undervalued And Likely To Outperform

November 15, 2022 | finance.yahoo.com

Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

November 14, 2022 | finance.yahoo.com

Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today

November 11, 2022 | finance.yahoo.com

Here's Why Catalyst Pharmaceuticals (NASDAQ:CPRX) Has Caught The Eye Of Investors

November 10, 2022 | seekingalpha.com

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Call Transcript

November 9, 2022 | finance.yahoo.com

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

November 9, 2022 | finance.yahoo.com

Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates

November 8, 2022 | nasdaq.com

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

November 7, 2022 | finance.yahoo.com

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

November 4, 2022 | fool.com

Catalyst Pharmaceuticals (NASDAQ: CPRX)

October 25, 2022 | finance.yahoo.com

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

October 20, 2022 | finance.yahoo.com

5 Stocks to Bet on in an Innovation-Driven Drug Industry

October 20, 2022 | uk.finance.yahoo.com

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

October 18, 2022 | finance.yahoo.com

The 6.3% return this week takes Catalyst Pharmaceuticals' (NASDAQ:CPRX) shareholders five-year gains to 375%

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPRX Company Calendar

Last Earnings: 11/09/2021
Today: 12/06/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/15/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CPRX
CUSIP: N/A
CIK: 1369568
Web: www.catalystpharma.com
Phone: (305) 420-3200
Fax: 305-529-0933
Employees: 76
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $17.13
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $15.50
Forecasted Upside/Downside: +4.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.61
Trailing P/E Ratio: 26.98
Forward P/E Ratio: 22.55
P/E Growth: N/A
Net Income: $39.48 million
Net Margins: 34.90%
Pretax Margin: 44.08%
Return on Equity: 28.53%
Return on Assets: 24.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.18
Quick Ratio: 6.02

Sales & Book Value

Annual Sales: $140.83 million
Price / Sales: 12.16
Cash Flow: $0.37 per share
Price / Cash Flow: 44.56
Book Value: $2.01 per share
Price / Book: 8.19

Miscellaneous

Outstanding Shares: 104,071,000
Free Float: 89,397,000
Market Cap: $1.71 billion
Optionable: Optionable
Beta: 1.25

Social Links

Key Executives

Mr. Patrick J. McEnany (Age 75)
Co-Founder, Chairman, Pres & CEO
Comp: $1.05M

Ms. Alicia Grande C.M.A. (Age 51)
CPA, CMA, CPA, Chief Accounting Officer, VP, Treasurer & CFO
Comp: $617.94k

Dr. Steven R. Miller (Age 60)
COO & Chief Scientific Officer
Comp: $745.71k

Dr. Gary Ingenito M.D. (Age 66)
Ph.D., Chief Medical & Regulatory Officer
Comp: $706.86k

Dr. Preethi Sundaram Ph.D. (Age 46)
Chief Strategy Officer
Comp: $511.25k

Ms. Mary Coleman
VP & Head of Investor Relations

Mr. Brian Elsbernd J.D. (Age 58)
Chief Compliance Officer & Chief Legal Officer

Mr. Pete Curry Sr.
VP of Sales

Mr. Jeffrey Del Carmen (Age 51)
Chief Commercial Officer

Mr. Philip B. Schwartz (Age 67)
Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CPRX Stock - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.
What is Catalyst Pharmaceuticals' stock price forecast for 2023?: 4 Wall Street analysts have issued 1 year target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $18.00. On average, they predict the company's stock price to reach $17.13 in the next twelve months. This suggests a possible upside of 4.0% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.
How have CPRX shares performed in 2022?: Catalyst Pharmaceuticals' stock was trading at $6.77 at the beginning of 2022. Since then, CPRX stock has increased by 143.1% and is now trading at $16.46.
View the best growth stocks for 2022 here.
Are investors shorting Catalyst Pharmaceuticals?: Catalyst Pharmaceuticals saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 6,670,000 shares, a drop of 17.2% from the October 31st total of 8,060,000 shares. Based on an average daily volume of 3,260,000 shares, the short-interest ratio is currently 2.0 days. Currently, 6.8% of the company's shares are short sold.
View Catalyst Pharmaceuticals' Short Interest.
When is Catalyst Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast.
How were Catalyst Pharmaceuticals' earnings last quarter?: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, hitting analysts' consensus estimates of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analysts' expectations of $34.47 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%. During the same period in the prior year, the company earned $0.11 EPS.

What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings?: Catalyst Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.
What other stocks do shareholders of Catalyst Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).
What is Catalyst Pharmaceuticals' stock symbol?: Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
Who are Catalyst Pharmaceuticals' major shareholders?: Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.67%), State Street Corp (7.26%), Vanguard Group Inc. (5.90%), LSV Asset Management (3.30%), Renaissance Technologies LLC (2.14%) and Dimensional Fund Advisors LP (2.08%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.
How do I buy shares of Catalyst Pharmaceuticals?: Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Catalyst Pharmaceuticals' stock price today?: One share of CPRX stock can currently be purchased for approximately $16.46.
How much money does Catalyst Pharmaceuticals make?: Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.71 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.
How can I contact Catalyst Pharmaceuticals?: Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.

This page (NASDAQ:CPRX) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial